{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T05:13:26Z","timestamp":1778303606298,"version":"3.51.4"},"reference-count":83,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2016,6,29]],"date-time":"2016-06-29T00:00:00Z","timestamp":1467158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:p>Treatment options for chronic lymphocytic leukemia, the most common leukemia in the United States, have expanded rapidly in recent years. While traditional chemoimmunotherapy still remains a mainstay for young, fit patients, a number of novel targeted therapies have emerged that have changed the therapeutic landscape. Two innovative anti-CD20 monoclonal antibodies, obinutuzumab and ofatumomamab, have demonstrated activity in chronic lymphocytic leukemia and represent well-tolerated options in upfront management of elderly patients or in those with significant comorbidities. Agents targeting the B-cell receptor pathway, ibrutinib and idelalisib, have excellent activity in chronic lymphocytic leukemia, particularly in those patients with 17p deletions, in which responses to chemoimmunotherapy are traditionally dismal. Venetoclax (ABT-199), the recently FDA-approved BCL2 inhibitor, as well as several other agents and therapy combinations in the pipeline offer great promise for patients with chronic lymphocytic leukemia, particularly in the relapsed\/refractory setting. This article comprehensively reviews the data for novel agents in chronic lymphocytic leukemia, including the pharmacology of therapies, unique toxicities, and other practical management considerations for clinicians.<\/jats:p>","DOI":"10.1177\/1078155216656929","type":"journal-article","created":{"date-parts":[[2016,6,29]],"date-time":"2016-06-29T20:58:18Z","timestamp":1467233898000},"page":"502-517","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia"],"prefix":"10.1177","volume":"23","author":[{"given":"Bernard L","family":"Marini","sequence":"first","affiliation":[{"name":"Department of Pharmacy Services and Clinical Sciences, University of Michigan Health System and College of Pharmacy, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Samanas","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services and Clinical Sciences, University of Michigan Health System and College of Pharmacy, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony J","family":"Perissinotti","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services and Clinical Sciences, University of Michigan Health System and College of Pharmacy, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2016,6,29]]},"reference":[{"key":"bibr1-1078155216656929","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21254"},{"key":"bibr2-1078155216656929","unstructured":"SEER Cancer Statistics Factsheets: Chronic lymphocytic leukemia. Bethesda, MD: National Cancer Institute, http:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html (2015, accessed 23 January 2016)."},{"key":"bibr3-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(00)00038-2"},{"key":"bibr4-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1023\/A:1020608328969"},{"key":"bibr5-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012283432602"},{"key":"bibr6-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-379966"},{"key":"bibr7-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-429282"},{"key":"bibr8-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-395673"},{"key":"bibr9-1078155216656929","unstructured":"National Comprehensive Cancer Network (NCCN).\n                      NCCN clinical practice guidelines in oncology\n                      . Non Hodgkin\u2019s Lymphomas Version 1.2016. Washington, PA: National Comprehensive Cancer Network."},{"key":"bibr10-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2010.167"},{"key":"bibr11-1078155216656929","unstructured":"US Food and Drug Administration. Center for drug evaluation and research, http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/125486Orig1s000CDTL.pdf (2013, accessed January 14 2016)."},{"key":"bibr12-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61381-5"},{"key":"bibr13-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651125"},{"key":"bibr14-1078155216656929","doi-asserted-by":"crossref","unstructured":"Eichhorst B, Fink AM, Busch R, et\u00a0al. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study). In:\n                      ASH 2014\n                      , San Francisco, CA, Abstract 19, 2004. Washington, DC: ASH.","DOI":"10.1182\/blood.V124.21.19.19"},{"key":"bibr15-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60027-7"},{"key":"bibr16-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984"},{"key":"bibr17-1078155216656929","doi-asserted-by":"crossref","unstructured":"Goede V, Fischer K, Bosch F, et\u00a0al. Updated survival analysis from the CLL11 study: Obinutuzumab versus rituximab in chemoimmunotherapy-treated patients with chronic lymphocytic leukemia. In:\n                      ASH 2015\n                      , Orlando, FL, Abstract 1733, 2015. Washington, DC: ASH.","DOI":"10.1182\/blood.V126.23.1733.1733"},{"key":"bibr18-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"bibr19-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-606038"},{"key":"bibr20-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"bibr21-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315226"},{"key":"bibr22-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513257"},{"key":"bibr23-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-140582"},{"key":"bibr24-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-667675"},{"key":"bibr25-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-647925"},{"key":"bibr26-1078155216656929","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.1.362"},{"key":"bibr27-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.3187"},{"key":"bibr28-1078155216656929","doi-asserted-by":"crossref","unstructured":"Huang H, Li XY, Li HR, et\u00a0al. Preventing hepatitis B reactivation in HBsAg-positive patients with untreated diffuse large B-cell lymphoma with R-CHOP chemotherapy: A prospective study to compare entecavir and lamivudine. In:\n                      ASCO 2013\n                      , Chicago, IL, Abstract 8503, 2013. Alexandria, VA: ASCO.","DOI":"10.1200\/jco.2013.31.15_suppl.8503"},{"key":"bibr29-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-330357"},{"key":"bibr30-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000107"},{"key":"bibr31-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-296913"},{"key":"bibr32-1078155216656929","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S71839"},{"key":"bibr33-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2013.07.002"},{"key":"bibr34-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2004.05.014"},{"key":"bibr35-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.12.21"},{"key":"bibr36-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-338855"},{"key":"bibr37-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.11.012"},{"key":"bibr38-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20011866"},{"key":"bibr39-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-328484"},{"key":"bibr40-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12333"},{"key":"bibr41-1078155216656929","author":"Brown JR","year":"2014","journal-title":"ASH 2014, San Francisco, CA, Abstract 3331,\u2013"},{"key":"bibr42-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71182-9"},{"key":"bibr43-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-604272"},{"key":"bibr44-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0606663104"},{"key":"bibr45-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621466"},{"key":"bibr46-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.247"},{"key":"bibr47-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9822(98)70471-3"},{"key":"bibr48-1078155216656929","unstructured":"Imbruvica\n                      [package insert]. Sunnyvale, CA: Pharmacyclics. Last revised January 2015. Available at: https:\/\/www.imbruvica.com\/docs\/librariesprovider7\/default-document-library\/prescribing_information.pdf."},{"key":"bibr49-1078155216656929","doi-asserted-by":"crossref","unstructured":"Jones JA, Hillmen P, Coutre S, et\u00a0al. Pattern of use of anticoagulation and\/or antiplatelet agents in patients with chronic lymphocytic leukemia (CLL) treated with single-agent ibrutinib therapy. In:\n                      ASH 2014\n                      , San Francisco, CA, Abstract 1990, 2014. Washington, DC: ASH.","DOI":"10.1182\/blood.V124.21.1990.1990"},{"key":"bibr50-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20020805"},{"key":"bibr51-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.9.4330"},{"key":"bibr52-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1038\/nri1056"},{"key":"bibr53-1078155216656929","doi-asserted-by":"crossref","unstructured":"Sharman JP, Coutre SE, Furman RR, et\u00a0al. Second interim analysis of a phase 3 study of idelalisib (ZYDELIG\u00ae) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): Efficacy analysis in patient subpopulations with del(17p) and other adverse prognostic factors. In:\n                      ASH 2014\n                      , Abstract 330, 2014.","DOI":"10.1182\/blood.V124.21.330.330"},{"key":"bibr54-1078155216656929","doi-asserted-by":"crossref","unstructured":"Coutre S, Barrientos JC, Brown J, et\u00a0al. Safety of idelalisib in B-cell malignancies: Integrated analysis of eight clinical trials. In:\n                      ASCO 2015\n                      , Chicago, IL, Abstract e18030. Alexandria, VA: ASCO.","DOI":"10.1200\/jco.2015.33.15_suppl.e18030"},{"key":"bibr55-1078155216656929","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1022770"},{"key":"bibr56-1078155216656929","unstructured":"Zydelig\n                      [package insert]. Foster City, CA: Gilead Sciences. Last revised July 2014. Available at: http:\/\/www.gilead.com\/~\/media\/Files\/pdfs\/medicines\/oncology\/zydelig\/zydelig_pi.pdf."},{"key":"bibr57-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-527853"},{"key":"bibr58-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.122"},{"key":"bibr59-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083830"},{"key":"bibr60-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-585869"},{"key":"bibr61-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-617522"},{"key":"bibr62-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70335-3"},{"key":"bibr63-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-535047"},{"key":"bibr64-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-015-0157-x"},{"key":"bibr65-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0781"},{"key":"bibr66-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093906"},{"key":"bibr67-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0901217"},{"key":"bibr68-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2014.05.008"},{"key":"bibr69-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3722"},{"key":"bibr70-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2008.01.007"},{"key":"bibr71-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2011.10.001"},{"key":"bibr72-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-5836"},{"key":"bibr73-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.7898"},{"key":"bibr74-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4402081"},{"key":"bibr75-1078155216656929","unstructured":"Venclexta\n                      [package insert]. North Chicago, IL: AbbVie, Inc. Last revised April 2016. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/208573s000lbl.pdf."},{"key":"bibr76-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29566"},{"key":"bibr77-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2014.218"},{"key":"bibr78-1078155216656929","doi-asserted-by":"crossref","unstructured":"Parikh SA, Chaffee KR, Call TG, et\u00a0al. Ibrutinib therapy for chronic lymphocytic leukemia (CLL): An analysis of a large cohort of patients treated in routine clinical practice. In:\n                      ASH 2015\n                      , Orlando, FL, Abstract 2935, 2015. Washington, DC: ASH.","DOI":"10.1182\/blood.V126.23.2935.2935"},{"key":"bibr79-1078155216656929","doi-asserted-by":"crossref","unstructured":"Sandoval-Sus JD, Chavez JC, Dalia S, et\u00a0al. Outcomes of patients with relapsed\/refractory chronic lymphocytic leukemia after ibrutinib discontinuation outside clinical trials: a single institution experience. In:\n                      ASH 2015\n                      , Orlando, FL, Abstract 2945, 2015. Washington, DC: ASH.","DOI":"10.1182\/blood.V126.23.2945.2945"},{"key":"bibr80-1078155216656929","doi-asserted-by":"crossref","unstructured":"Barrientos JC, Kaur M, Mark A, et\u00a0al. Outcomes of patients with chronic lymphocytic leukemia (CLL) after idelalisib therapy discontinuation. In:\n                      ASH 2015\n                      , Orlando, FL, Abstract 4155, 2015. Washington, DC: ASH.","DOI":"10.1182\/blood.V126.23.4155.4155"},{"key":"bibr81-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-585075"},{"key":"bibr82-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-560284"},{"key":"bibr83-1078155216656929","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1304"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155216656929","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155216656929","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155216656929","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:16:51Z","timestamp":1777688211000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155216656929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,29]]},"references-count":83,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1177\/1078155216656929"],"URL":"https:\/\/doi.org\/10.1177\/1078155216656929","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,29]]}}}